Michael Cherny
Stock Analyst at B of A Securities
(5.00)
# 6
Out of 4,827 analysts
108
Total ratings
55.56%
Success rate
136.64%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $16.82 | +36.74% | 11 | Apr 29, 2025 | |
| MCK McKesson | Maintains: Buy | $665 → $755 | $722.37 | +4.52% | 12 | Apr 11, 2025 | |
| CAH Cardinal Health | Maintains: Buy | $150 → $155 | $153.48 | +0.99% | 11 | Apr 11, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $299.65 | +10.13% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $52.35 | -23.59% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $66.78 | +12.31% | 11 | Feb 13, 2025 | |
| PGNY Progyny | Maintains: Buy | $21 → $25 | $23.44 | +6.66% | 10 | Feb 11, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $58.14 | +54.81% | 2 | Feb 7, 2025 | |
| ALGN Align Technology | Upgrades: Outperform | $235 → $280 | $172.22 | +62.58% | 2 | Jan 6, 2025 | |
| DGX Quest Diagnostics | Upgrades: Outperform | $135 → $174 | $176.57 | -1.46% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $66.50 | +26.32% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $153.11 | +61.98% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $138.88 | +83.61% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.66 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $304.58 | -9.71% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.53 | +1,533.99% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $23 → $22 | $11.05 | +99.10% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $246.46 | +5.50% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $23 | $23.10 | -2.58% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $3.80 | +110.53% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $11.45 | +65.94% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $6.86 | +147.81% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $8.44 | +522.04% | 2 | Jan 5, 2022 |
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $16.82
Upside: +36.74%
McKesson
Apr 11, 2025
Maintains: Buy
Price Target: $665 → $755
Current: $722.37
Upside: +4.52%
Cardinal Health
Apr 11, 2025
Maintains: Buy
Price Target: $150 → $155
Current: $153.48
Upside: +0.99%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $299.65
Upside: +10.13%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $52.35
Upside: -23.59%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $66.78
Upside: +12.31%
Progyny
Feb 11, 2025
Maintains: Buy
Price Target: $21 → $25
Current: $23.44
Upside: +6.66%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $58.14
Upside: +54.81%
Align Technology
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $172.22
Upside: +62.58%
Quest Diagnostics
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $176.57
Upside: -1.46%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $66.50
Upside: +26.32%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $153.11
Upside: +61.98%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $138.88
Upside: +83.61%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $13.66
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $304.58
Upside: -9.71%
Apr 22, 2024
Initiates: Outperform
Price Target: $25
Current: $1.53
Upside: +1,533.99%
Mar 18, 2024
Maintains: Market Perform
Price Target: $23 → $22
Current: $11.05
Upside: +99.10%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $246.46
Upside: +5.50%
Feb 26, 2024
Initiates: Market Perform
Price Target: $23
Current: $23.10
Upside: -2.58%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $3.80
Upside: +110.53%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $11.45
Upside: +65.94%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $6.86
Upside: +147.81%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $8.44
Upside: +522.04%